Recent advances in the management of nasopharyngeal carcinoma
Publication in refereed journal

Times Cited
Altmetrics Information

Other information
AbstractOver the last few years, certain areas in the management nasopharyngeal carcinoma (NPC) that have an impact on the care of these patients have evolved, particularly with regard to liquid biopsies, minimally invasive surgery, and advances in chemotherapy and immunotherapy. Beyond its proven role in the diagnostics, surveillance, and treatment of NPC, liquid biopsy with plasma Epstein–Barr virus DNA in the screening of high-risk populations for NPC is strongly supported by recent evidence. Surgery of the nasopharynx is reserved for locally recurrent NPC, and in recent years there have been great strides in minimally invasive techniques with survival rates similar to those of open techniques in treating NPC. Induction chemotherapy in a recent pooled analysis was shown to be superior to concurrent chemotherapy alone for locoregionally advanced NPC. Finally, immunotherapy with a PD-1 inhibitor in NPC has been shown to have 1-year overall survival rates comparable to those of other patients with heavily pre-treated metastatic or recurrent NPC. In this commentary, we discuss these recent advances and their potential in the clinical management of patients with NPC.
Acceptance Date12/11/2018
All Author(s) ListLam W.K.J., Chan J.Y.K.
Journal nameF1000Research
Volume Number7
PublisherNLM (Medline)
Article number1829
LanguagesEnglish-United Kingdom
KeywordsEBV DNA, immunotherapy, endoscopic surgery, nasopharyngectomy, Nasopharyngeal carcinoma, robotic surgery

Last updated on 2020-17-11 at 01:51